Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tobira Therapeutics Inc.

Division of Allergan PLC
www.tobiratherapeutics.com

Latest From Tobira Therapeutics Inc.

Genfit Thinks Intercept’s Lead In NASH Not As Wide As Perceived

Genfit believes elafibranor’s clean tolerability and safety profile may help narrow the gap between it and Intercept’s OCA, with safety questions delaying OCA’s entry to market. Part two of Scrip’s interview with Genfit’s CEO and COO.

Business Strategies Clinical Trials

Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors

Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.

Deals Business Strategies

Conatus Accepts Defeat For Emricasan In NASH

After multiple Phase IIb trial failures, Conatus says it will fulfill contractual obligations and consider strategic alternatives. Partner Novartis was already focused on other candidates and partnerships in NASH.

Clinical Trials Business Strategies

Allergan Endures Another R&D Setback With Rapastinel Failing Three Pivotal Studies

Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.

Research & Development Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Inflammation
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Laurent Fischer, MD, Chmn. & CEO
    Christopher Peetz, CFO
    Eric Lefebvre, MD, CMO
    Helen Jenkins, COO
    Pamela Vig, PhD, VP, Clinical Research & Discovery
  • Contact Info
  • Tobira Therapeutics Inc.
    Phone: (650) 741-6625
    701 Gateway Blvd.
    Ste. 300
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register